cyrilzakka/clinical-trials huggingface dataset:
Large Language Models to Aid Gynecological Oncology Treatment

This trial aims to assess the impact of providing medical students with access to large language models, in comparison to treatment guideline pdfs, on treatment concordance with a conventional multidisciplinary tumor board

Advanced artificial intelligence (AI) technologies, particularly large language models such as OpenAI's ChatGPT, hold significant potential for enhancing medical decision-making. While ChatGPT was not specifically designed for medical applications, it has shown utility in various healthcare scenarios, including answering patient inquiries, drafting medical documentation, and aiding clinical consultations. Despite these advancements, its role in supporting treatment decision-making-particularly in complex oncological cases-remains underexplored.

Treatment decision-making in gynecological oncology is a multifaceted process that integrates evidence-based guidelines, tumor biology, patient-specific factors, and clinical expertise. AI tools like ChatGPT could potentially assist in synthesizing relevant guideline-based recommendations, improving decision accuracy, and facilitating more efficient clinical workflows. However, ChatGPT is not specifically tailored for oncological treatment decisions and lacks comprehensive validation in this domain. Additionally, it may generate misinformation or plausible-sounding but inaccurate recommendations, which could impact clinical judgment. Therefore, understanding how medical professionals, including students and early-career physicians, interact with such AI tools is essential before broader integration into clinical practice. Locally deployable models, such as Llama, enable secure, on-premise usage while retrieval-augmented generation ensures guideline-compliant recommendations.

This study will investigate the impact of language models on treatment decision support for medical students managing gynecological oncology cases. This is a crossover study, where participants will be randomized into two groups. All participants begin with access to ChatGPT for two vignettes. They then proceed with two cases using either a locally deployed language model, followed by two cases relying on guideline PDFs, or vice versa.

Each participant will analyze clinical cases, propose treatment plans, and rate their confidence in their decisions and decision support system usability. This study aims to provide insights into the potential benefits and limitations of integrating AI tools like ChatGPT into oncological treatment decision-making.

Eligibility Criteria:
Inclusion Criteria:

- Medical students having started with clinical subjects

Exclusion Criteria:

- Not being a medical student
Active Bathing to Eliminate Infection (ABATE Infection) Trial

The ABATE Infection Project is a cluster randomized trial of hospitals to compare two quality improvement strategies to reduce multi-drug resistant organisms and healthcare-associated infections in non-critical care units. The two strategies to be evaluated are:

* Arm 1: Routine Care Routine policy for showering/bathing
* Arm 2: Decolonization Use of chlorhexidine as routine soap for showering or bed bathing for all patients Mupirocin x 5 days if MRSA+ by history, culture, or screen

Note that enrolled "subjects" represents 53 individual HCA Hospitals (representing \~190 non-critical care units) that have been randomized.


Eligibility Criteria:
Inclusion Criteria:

* All HCA hospitals that reside in the United States
* Note: Unit of randomization is the hospital, but the participants are hospital units

Exclusion Criteria:

* Non-critical care units where chlorhexidine bathing or decolonization for MRSA+ non-critical care patients is routine
* Pediatric, peri-partum, rehabilitation, psychiatry, and BMT units
* Units with \>30% cardiac or hip/knee orthopedic surgeries
* Unit average length of stay \<2 days
* Patients \<12 years-old
* Patients with known allergy to mupirocin or chlorhexidine
Mobile Health Intervention for Active Tuberculosis

The purpose of this study is to evaluate and further refine a mobile support tool for patients receiving treatment for active tuberculosis. Half of participants will receive support and monitoring using a mobile phone software application and usual care, while the other half will receive usual care.

Tuberculosis (TB) remains a top ten leading cause of death globally despite it being a largely curable disease. New effective treatment supervision strategies are needed particularly in low-resource high TB burden settings and a potential solution is in the hands of nearly every patient - a mobile phone. Modern modular design mobile phone software applications ("apps") hold great promise to address this unmet need.

Current technologies allows for rapid design modification based on end user needs, implementation of native operating system (e.g., Android) versions for users with inconsistent internet access, and the integration of the patients' experiences with electronic health records using industry standards. Apps can perform multiple functions (e.g., automated reminders, symptom tracking, secure messaging, multi-media education). To date, few TB related apps have focused on patients as users, and none support patient engagement in self-management of their care or direct adherence monitoring. The research objectives are to understand end user needs and other stakeholder needs to build, refine, and pilot test an app to support patients self-administering treatment for active TB.

Eligibility Criteria:
Inclusion Criteria:

* Subject is starting TB treatment for the first time
* Subject has no known TB drug resistance
* Subject is HIV negative (self-reported or documented)
* Subject owns or has regular access to a mobile phone that can access the Internet and is able to operate the mobile phone to communicate or have someone able to assist.

Exclusion Criteria:

* Severely ill (i.e., requiring hospitalization)
* Reside in the same household with another study participant
* History of known drug resistance and HIV co-infection because their care is managed separately and the treatment regimens and duration differ.
Definition of Biomechanical Indices Measurable During Sport Movements for the Prevention of Primary and Secondary ACL Injury

The aim of the study is to define a set of quantitative parameters related to articular biomechanics, which will be evaluated during some specific motor tasks. The goal is the prevention of primary and secondary anterior cruciate ligament injury in athletes.

Specifically, the validation of a new comparative methodology of biomechanics analysis will be performed, based on inertial sensors and musculoskeletal models. This way, brief but exhaustive description of functional characteristics of athletes could be created and easily used in ambulatory environment.


Eligibility Criteria:
Inclusion Criteria:

* Healthy subjects, men of women, 18 years old minimum and 50 maximum, which read and signed the informed consent

Exclusion Criteria:

* evidence of any kind of musculoskeletal disease or impairment
* evidence of past surgical intervention to either lower or upper limbs
* age out of the inclusion range
* cardiac or pulmonary diseases
* inability to read and sign the informed consent
* inability to perform the motor tasks required
Phase 1 Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Injection of Cisplatin for Stage IV Lung Cancer

The goal of the study is to identify the maximum tolerated dose of endobronchial ultrasound-guided transbronchial injection (EBUS-TBNI) of cisplatin for Stage IV lung cancer.

Multiple studies have demonstrated feasibility and safety of delivering cisplatin directly into lung tumors using endobronchial ultrasound guided-transbronchial needle injection (EBUS-TBNI). This technique relies on the use of a bronchoscope with an integrated ultrasound transducer allowing real-time visualization of, and delivery of cisplatin into, tumors lying in proximity to the central airways. Prior work has utilized this technique to treat loco regional recurrence in a previously radiated field. The goal of the current study is to identify the initial dose for intratumoral cisplatin.

Eligibility Criteria:
Inclusion Criteria:

Age 18 years or above

Eastern Cooperative Oncology Group (ECOG) performance score 0-2

Have known or suspected metastatic NSCLC at time of enrollment (including patients who progress on initial therapy or are found to have metastatic disease during therapy and are not excluded based on 8.2 below).

Ability and willingness to provide informed consent

Rapid on-site cytopathologic examination (ROSE) performed during the procedure returns likely NSCLC (informed consent will occur prior to the procedure). No research procedures will be performed if ROSE is non-diagnostic.

A CT scan of the chest (with or without contrast) within the prior 3 months.

The presence of an EBUS accessible target site. These may be primary lung cancers or metastatic sites (including when a lymph node station has been replaced by metastatic tumor), that are accessible by EBUS

Patients must have adequate organ and marrow function as defined below:

* Leukocytes ≥3,000/mcL
* Platelets ≥100,000/mcL
* Total bilirubin ≤ institutional upper limit of normal (ULN)
* AST(SGOT)/ALT(SGPT) ≤ institutional ULN
* Glomerular filtration rate (GFR) ≥60 mL/min/1.73 m2 via CKD EPI)

Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial

Exclusion Criteria:

Use of an investigational agent in prior 30 days

Pregnancy/lactation

Treatment with cytotoxic chemotherapy within the past 30 days

Prior (within the last 12 months) or ongoing radiation treatment to the study NSCLC

Allergy to cisplatin or its derivatives

Patient not appropriate for the research study based on physician discretion
An Observational Study of Xeloda (Capecitabine) in Participants With Metastatic or Advanced Breast Cancer

This observational study will evaluate the routine clinical use and the safety and efficacy of capecitabine (Xeloda®) in participants with metastatic or advanced breast cancer. Eligible participants will be followed for up to 24 months.


Eligibility Criteria:
Inclusion Criteria:

* Adult female participants, \>/= 18 years of age
* Cytologic/histopathologic confirmed diagnosis of metastatic breast cancer
* Prescribed capecitabine as in routine clinical practice
* Informed consent signed

Exclusion Criteria:

* Participation in any other clinical trial
* History of severe and unexpected reactions to fluoropyrimidine therapy
* Hypersensitivity to capecitabine or to any of the excipients of fluorouracil
* Known dihydropyrimidine dehydrogenase (DPD) deficiency
* Pregnant or lactating women
* Severe leucopenia, neutropenia, or thrombocytopenia
* Severe hepatic impairment
* Severe renal impairment (creatinine clearance below 30 ml/min)
* Treatment with sorivudine or its chemically related analogues, such as brivudine
* Refusal to give consent
Gefitinib Usage and Outcomes in Routine Treatment

The purpose of this study is to understand real world gefitinib usage patterns, patient characteristics and outcomes and to present these for a Caucasian population

A multicentre, retrospective chart review study to characterise gefitinib usage and outcomes in routine treatment

Eligibility Criteria:
Inclusion Criteria:

* Patients who received gefitinib first line in the UK Single Payment Access (SPA) scheme
* Locally advanced or metastatic EGFR mutation positive NSCLC
* Supplied with first pack of gefitinib prior to 1st January 2012

Exclusion Criteria:

* Patient was treated privately (i.e. outside the NHS)
* Gefitinib was second-line therapy following treatment failure on a prior therapy
Magnesium Lactate in the Reduction of Gestational Diabetes Incidence.

Gestational diabetes, occurs during the second or third trimester of pregnancy, with no prior history of diabetes; this entity can be resolved at the end of pregnancy. Magnesium is the fourth most abundant mineral in the body, It plays an essential role in the regulation of insulin metabolism, in the functions of adenosine triphosphate. In Mexico, the prevalence of hypomagnesemia is 36.3% for women. Findings suggesting that magnesium supplementation may be a beneficial indication in metabolic glucose disorders. The hypothesis of this study is: that Magnesium lactate administration is safe and reduces the incidence of gestational diabetes.

Objective: This study aims to evaluate the efficacy and safety of magnesium lactate oral administration in reducing the gestational diabetes incidence.

Design: Randomized, double-blind, placebo-controlled clinical trial.

Study population: Pregnant women aged 19 to 35 years, in the twelfth week of pregnancy, whit hypomagnesemia and without the concomitant disease.

Study groups: an intervention group and a control group.

Sample size: It was calculated using a statistical power of 80%, an alpha value of 0.05; 15% of the difference in the mean of gestational diabetes incidence control group and intervention groups was considered. The estimated sample size was 110 subjects for each group.

Process: All eligible participants according to inclusion and exclusion criteria, will be randomized to one of the study groups.

The intervention group will receive magnesium lactate, 2 tablets orally every 12 hours (equivalent to 360 mg of elemental magnesium) for 3 months plus baseline dietary magnesium requirement; the control group will receive 2 tablets orally every 12 hours of on inert placebo for three months plus baseline dietary magnesium requirement.

The blood concentrations of glucose, triglycerides, magnesium, creatinine, transaminases, and thyroid hormones will be measured, as well as the anthropometric measurements, at baseline and end conditions. Also, an oral glucose tolerance curve will be realized at the 20th gestation week.

Statistical analysis: Numerical values will be expressed as mean ± standard deviation; categorical variables will be expressed as proportions. Differences between the groups were estimated by unpaired Student t-test for numerical variables (Mann-Whitney U test for skewed data) or Chi-square and Fisher´s exact test for categorical variables. Intragroup differences were estimated by paired Student t-test.

Eligibility Criteria:
Inclusion Criteria:

* Pregnant women aged 19 to 35 years.
* 12th to 14th gestation weeks.
* Informed consent of the participant.

Exclusion Criteria:

* Diabetes.
* High blood pressure.
* Hypertriglyceridemia (\>250 g/dL)
* Neoplasia disease.
* Thyroid disease.
* Hepatic disease.
* Consumption of alcoholic beverages.
* Smoking.
* Medication use (thiazide diuretics, anti-blocking agents, calcium antagonists, statins, nicotinic acid, phenytoin, valproic acid, antidepressants, beta-adrenergic, theophylline, glucocorticoids, in the last year)
Calorie Restriction With Leucine Supplementation

The purpose of this study is to determine whether consuming additional leucine during calorie restriction induced weight loss has beneficial or harmful effects on multi-organ (liver, muscle, adipose tissue) insulin sensitivity, colonocyte proliferation rates, the gut microbiome, muscle mass and function, and bone mineral density in obese, postmenopausal women.


Eligibility Criteria:
Inclusion Criteria:

* Obese with body mass index (BMI) between 30 and 40 kg/m2
* Postmenopausal
* Sedentary (i.e., less than 1.5 hours of exercise per week)

Exclusion Criteria:

* Individuals with diabetes and/or uncontrolled hypertension
* Individuals with hepatitis B and/or C
* Individuals who smoke
* Individuals with an allergy to whey protein
Beta Blockade in Critical Injury

Critically injured patients endure a period of hypermetabolism/catabolism after being resuscitated. The metabolic cost of this may be measured in loss of lean body mass, poor wound healing, susceptibility to infection and long hospital stays. While there have been some data to suggest that hypermetabolism can be ameliorated in burn patients by beta blockade, to our knowledge, a prospective trial in trauma patients has not yet been done. Our hypothesis is that nonselective beta blockade will reduce catabolism, improve glucose control, blunt loss of lean body mass, decrease infections and improve outcome in a cohort of critically injured patients.


Eligibility Criteria:
Inclusion Criteria:

* ISS\>25, stable at 48 hours after injury
* Fully resuscitated
* Ventilated

Exclusion Criteria Include:

* Intracranial hypertension requiring active treatment
* Hypotension/Pressors
* Already on beta blocker for a standard indication
Pharmacokinetics of BPV Following Bilateral US-guided TAP Block for C-section

The transversus abdominis plane block (TAP block) is an effective method of postoperative pain management after cesarean section (C-section). Up to now, there are no data available about bupivacaine (BPV) plasma levels after TAP block in adults. In the current study, the investigators aimed to assess BPV pharmacokinetic parameters after ultrasound-guided TAP block using BPV in parturients undergoing C-section and to report its effects on corrected QT interval.

The investigators led a prospective observational study in pregnant women undergoing elective C-section under spinal anesthesia (SA) using 10 mg of hyperbaric BPV. After surgery, they received bilateral ultrasound-guided TAP block with 50 mg of BPV in each side. Venous blood samples were collected immediately before and at 10, 30, 45, 60, 90, 120, 180, 240, 720 and 1440 minutes after both TAP blocks. The investigators used high performance liquid chromatography (HPLC) to measure BPV total plasma concentrations. Mean BPV area under the curve (AUC) was calculated from 0 to 24 hours according to the linear trapezoidal rule. Mean peak of total BPV plasma concentration (Cmax) and time to reach the peak (Tmax) were recorded. Electrocardiographic (ECG) recordings were also repeated at 1, 2, 3 and 4 hours to investigate the effect of BPV on corrected QT (QTc) intervals. Data were computed using SPSS 20®. Quantitative data were expressed as means ± SD. Qualitative data were expressed as percentages.

Eligibility Criteria:
Inclusion Criteria:

ASA physical status I-II pregnant women scheduled for elective C-section with Pfannenstiel incision under Spinal anesthesia

Exclusion Criteria:

* ASA physical status \> II,
* known allergy to local anesthetics,
* body mass index (BMI) more than 40 kg/m²,
* coagulation disorders,
* neurologic or neuromuscular disease,
* significant liver or renal dysfunction,
* electrolyte disturbances,
* heart arrhythmias,
* corrected QT (QTc) interval\> 0.47s
* patients taking drugs that may prolong QT interval.
Safety of Primaquine + Artemether-lumefantrine in G6PD Deficient Males With an Asymptomatic Malaria Infection (SAFEPRIM)

The purpose of this study is to evaluate the tolerability and safety of increasing doses of primaquine in combination with artemether-lumefantrine in G6PD deficient males with an asymptomatic P. falciparum malaria infection.


Eligibility Criteria:
Inclusion Criteria:

1. Male gender
2. Age ≥18 years and ≤45 years
3. BMI ≥16
4. P. falciparum parasitaemia at any density
5. G6PD deficiency by Beutler Fluorescent Spot test for intervention groups and control group receiving AL only (N=50)
6. G6PD normal activity by Beutler Fluorescent Spot test for control groups (N=20)
7. Informed consent by participant

Exclusion Criteria:

1. Enrolled in another clinical trial
2. Fever \>37.5°C (tympanic) or history of fever in the last 24 hours
3. Evidence of severe illness / danger signs or active infection other than malaria
4. Known allergy to study medications
5. Hb \<11 g/dL
6. Antimalarials taken within the last 2 weeks
7. PQ taken within the last 4 weeks and blood transfusion within the last 90 days
8. Non-falciparum malaria co-infection
9. Current use of tuberculosis or anti-retroviral medication, sulphonamides, dapsone, nitrofurantoin, , nalidixic acid, ciprofloxacin, , methylene blue, toluidine blue phenazopyridine and co-trimoxazole.
10. History of severe chronic illness
Comparison of Retinal Perfusion Between Diabetic and Non-diabetic Patients With OCT Angiography After Cataract Surgery.

This study aims to compare the retinal perfusion between diabetic and non-diabetic patients with Optical Coherence Tomography（OCT） Angiography after cataract surgery, to thoroughly evaluate the retinal state of diabetics after surgery, and to find out the relationship between postoperative complications occurred in retina and diabetes.

In this study, we perform a completely comparison of retina state characteristic including the foveal avascular zone(FAZ),perifovea vessel density,parafovea vessel density,macular thickness,perifovea thickness,parafovea thickness in superficial and deep layers of retina with OCT Angiography after cataract surgery,and analysis on the differences of EGF,IFN-γ,IL-10,IL-12,IL-1β,IL-6,IL-8,IP-10,MCP-1,VEGF in aqueous humor before surgery between diabetic and non-diabetic patients and to explore the potential correlations between postoperative complications occurred in retina and diabetes.

Eligibility Criteria:
Inclusion Criteria:

1. Patients with age-related cataract and with willing to improve visual acuity by undergoing phacoemulsification and intraocular lens implantation surgery.
2. Type 2 diabetes diagnosis according to American Diabetes Association# Standards of Medical Care in Diabetes -2017(ADA, American Diabetes Association)
3. Willing to sign the consent form.

Exclusion Criteria:

1. having known maculopathy, proliferative diabetic retinopathy(PDR), diabetic macular edema.
2. with high myopia of spherical equivalent greater than -6.0 diopters or axial length (AXL) greater than 26 mm in either eye.
3. preexisting vein or artery occlusion,glaucoma, previous uveitis, a history of ocular trauma, laser treatment, intravitreal injections or intraocular surgeries.
4. patients who had complications during cataract surgery.

Elimination Criteria:

1. poor compliance
2. voluntary withdrawal
3. any other kind of situation that researchers consider not suitable for further study.